Overview A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2 Status: Completed Trial end date: 2020-09-08 Target enrollment: Participant gender: Summary Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study Phase: Phase 1 Details Lead Sponsor: Daewon Pharmaceutical Co., Ltd.